Xinrong Yang

180 Fenglin Rd
Xuhui, 200032, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 39 publications

Margin-enriched CD4+ central-memory T cells affect macrophages via ANXA1-FPR1 signaling axis to promote tumor progression in intrahepatic cholangiocarcinoma.

Margin-enriched CD4+ central-memory T cells affect macrophages via ANXA1-FPR1 signaling axis to promote tumor progression in intrahepatic cholangiocarcinoma.

Journal: International journal of biological sciences

Published: April 20, 2026

Two stable gut microbiome guilds predict liver tumor class and treatment responses.

Two stable gut microbiome guilds predict liver tumor class and treatment responses.

Journal: iMeta

Published: March 08, 2026

A multi-centre, prospective trial of a methylation-based liquid biopsy for early detection of liver cancer in high-risk populations.

A multi-centre, prospective trial of a methylation-based liquid biopsy for early detection of liver cancer in high-risk populations.

Journal: Clinical and translational medicine

Published: January 12, 2026

Glucose metabolic reprogramming as a driver of immunosuppression in the tumour microenvironment.

Glucose metabolic reprogramming as a driver of immunosuppression in the tumour microenvironment.

Journal: Clinical and translational medicine

Published: December 25, 2025

Primary Liver Cancer Trends Worldwide and in China: Analysis of GLOBOCAN 2022 Data and Disease Management Implications.

Primary Liver Cancer Trends Worldwide and in China: Analysis of GLOBOCAN 2022 Data and Disease Management Implications.

Journal: Portal hypertension & cirrhosis

Published: December 16, 2025

Circular RNAs in cancer: Its biogenesis, functions, relationships with cancer progression, applications in immunotherapy and biomarker potentials.

Circular RNAs in cancer: Its biogenesis, functions, relationships with cancer progression, applications in immunotherapy and biomarker potentials.

Journal: Cancer immunology, immunotherapy : CII

Published: July 09, 2025

Spatial‒temporal heterogeneities of liver cancer and the discovery of the invasive zone.

Spatial‒temporal heterogeneities of liver cancer and the discovery of the invasive zone.

Journal: Clinical and translational medicine

Published: January 13, 2025

Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial.

Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial.

Journal: The Lancet. Oncology

Published: December 16, 2024

China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition).

China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition).

Journal: Liver cancer

Published: November 04, 2024

EREG-secreting THBS1+ tissue monocytes are recruited by C5a to promote rapid liver regeneration in patients and mice during the ALPPS procedure.

EREG-secreting THBS1+ tissue monocytes are recruited by C5a to promote rapid liver regeneration in patients and mice during the ALPPS procedure.

Journal: Hepatobiliary surgery and nutrition

Published: July 23, 2024

Phosphoproteomics profiling of sorafenib-resistant hepatocellular carcinoma patient-derived xenografts reveals potential therapeutic strategies.

Phosphoproteomics profiling of sorafenib-resistant hepatocellular carcinoma patient-derived xenografts reveals potential therapeutic strategies.

Journal: iScience

Published: February 25, 2024

Platelet-mediated circulating tumor cell evasion from natural killer cell killing through immune checkpoint CD155-TIGIT.

Platelet-mediated circulating tumor cell evasion from natural killer cell killing through immune checkpoint CD155-TIGIT.

Journal: Hepatology (Baltimore, Md.)

Published: September 15, 2023

Showing 1-12 of 39

Last Updated: 09/26/2026